Derek Sloan is an experienced professional in the field of therapeutic product and process development, currently serving as Vice President at GenEdit since October 2020. Previously, Derek held various leadership roles, including Senior Director of Research at Vir Biotechnology, where significant advancements were made in CRISPR therapies, and Director of Research at Agenovir Corporation, focusing on gene therapy R&D and inventing multiple relevant patents. Derek's extensive background includes pivotal positions at Gilead Sciences, MedImmune, Immune Design Corp, and Cero Therapeutics, contributing to significant scientific advancements in areas such as HIV, cancer immunotherapy, and viral vectors. Derek obtained an MD from UC San Diego School of Medicine and a Bachelor’s degree in Immunology from UC Berkeley.
Org chart
Teams
Offices
This person is not in any offices
GenEdit
1 followers
GenEdit is focused on overcoming the major challenge to genetic medicines: Delivery. They aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible.
